Company Profile
Chugai Pharmaceutical
— A Roche Group company that develops drugs with proprietary antibody engineering and mid-sized molecule technologies, then delivers them through Roche’s global network
CH、AI PHARMACEUTICAL CO., LTD.61.12%It is a pharmaceutical company that continues to be listed on the Tosho Prime while having a parent company. From the viewpoint of drug discovery and DDS,Two in-house technologyContact Us 1, Dual-specific antibodies, etc. to bind two targets in one antibodyAntibody modification technology(Representative example of Hemophilia A) The other is to make the cyclic peptide of the middle size of the low、 and antibodyMedium」 technologySo, I made it from the original drug method to the dedicated factory. Sales revenue for FY2025¥2,579 billionResearch and Development Cost (Core)1,80 billion yenComment In this article, the entire company is concise,What to do with our technology, how to divide Roche and what to doFilter by
- In 30 seconds, Chugai Pharmaceutical and DDS standpoint position
- About logo and company name
- Where is this company in the world of drug discovery and DDS?
- Size of the company (the entire company is concise)
- Drug discovery and DDS resources
- Past Initiatives
- Future plans
- What is DDS?
- Collaboration mapping of drug discovery and DDS
- Technologies, Products and Services
- The risk of this company
- Glossary/Source/Ins ment and Source Response Table
1. Standing position in drug discovery and DDS
Nihonbashi MuromachiHead office in Kita-ku, Tokyo
( rights61.12 (Switzerland Roche Group
(antibody / medium))Rosh is responsible for overseas sales of original products.
Businesses related to drug discovery and DDS are largeBiotech and Contract Development Manufacturing (CDMO/CRO)3 types. Chugai PharmaceuticalPharmaceutical CompanyHome“Create” is a company that sells in the world.The division is clear FactsHome In the basic contract with Roche, Roche is about Chugai's development candidate productsFirst choice in Japan ()ing Korea and Taiwan)and On the contrary, Chugai can develop candidate productsFirst choice in Japanhas. For this reason, the company does not have any future development or sales network for the world,Focus on drug discovery technologyStructure The securities report expresses this form as “new business models different from ordinary corporate acquisitions and joint ventures.”
This article explains the company's technical strategy and business.Not medical adviceHome There is no intention to recommend the use of certain drugs or compare the effects of other drugs. Please contact your doctor for the treatment.
2. Logo and company name
Chugai Pharmaceutical Co., Ltd. is a trademark of Chugai. In this article, we do not reproduce the generated image,
Images obtained from the official websiteHome img/chugai_logo.svg Contact Us The logo contains a Roche group display.
Note: Chugai Pharmaceutical Co., Ltd. CHUGAI PHARMACEUTICAL CO., LTD.Home Parent companyRoche Holding Limited(Roche Holding Ltd.)F Hoffman La Roche LimitedComment Manufacturing is a subsidiaryChugai Pharmaceutical Co., Ltd.The factory name of this article (Ukima, Fujieda, Utsunomiya) refers to the company's factory.
Official Site:https://www.chugai-pharm.co.jp/3. Where is this company in the world of drug discovery and DDS?
This company is a feature of this company that is deeply involved in both the modification of antibodies and the oralization of peptides treated with peptides and GLP-1. The oral GLP-1 receptor activator (orforglipron) of low. is also produced by Chugai Pharmaceutical and is licensed to Eli Lilly.
4. Scope of the company (the entire company is concise)
| Index (Millions of yen) | FY2024 | FY2025 | FY2026 Forecast |
|---|---|---|---|
| Sales revenue | 11,706 | 12,579 | 13,450 |
| Research and Development Cost (Core) | 1,769 | 1,801 | ― |
| Operating income (Core) | 5,561 | 6,232 | 6,700 |
| Operating income (IFRS) | 5,420 | 5,988 | ― |
| Capital | ― | 634 | ― |
| (consolidated, year-end) | ― | 7,872 people | ― |
Chugai is a single segment of pharmaceutical business only.We do not disclose research and development costs by modalities. Undetermined / FutureFor the first half of FY2026 (Core), sales revenue was ¥6,633 billion (a 14.7% year-on-year increase), and operating income was ¥3,291 billion (a 2.0% increase). The company lists the reasons for the increase in royalty revenue, including exporting neblizumab for Roche, neMLizumab for Galderma. FactsFifty percent of operating income comes from sales.The structure of Galderma and Lilly, a company-created product sold overseas, and the structure earned from exports and loyalty.
5. Drug discovery and DDS resources
| Resource Types | ||
|---|---|---|
| People (Research Centers and Personnel) | Consolidated 7,872 people (end of 2025). Drug DevelopmentLife Science Park Yokohama(900 people)Ukima InstituteOverseas, Chugai Pharmabody Research, Singapore, takes on drug discovery research.Uncertainty regarding the number of people involved in medium or antibody modification | Facts |
| Gold (R&D expenses) | FY2025 1,80 billion yen(Core, 14.3% of revenue) | Facts |
| Gold (Research and medium) equipment) | Chugai Life Science Park Yokohama was established in 2022 with a budget of 1,288 billion yen. Fujieda served as a clinical trial drug and production facility for medium-sized antibody modifications.FJ2 190 billion yen (2022)FJ3 ¥55 billion (2024). CloseUKX(Low/Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-Medium-M | Facts |
| Gold (antibody equipment) | Biogenic Drugs Manufacturing Building in UtsunomiyaUT3Biogenic Drugs Manufacturing Building in Ukita (374ed to be completed in May 2014)UK3Remodeling (to be completed in June 2027) Capital investment in 2025: 634 billion yen | Facts |
| External investment, acquisition and introduction | US Corporate Venture CapitalOverseas Venture FundIn November 2025, he acquired Renaris Pharma and obtained the rights to sparsentan in Japan, Korea, and Taiwan. Most of our products are sourced from the group. | Facts |
| University/Research Organization/AI Company | Osaka University Immunology Frontier Research Center (IFReC)Comprehensive Partnership Agreement with (2016),Preferred NetworksComprehensive Partnership for Deep Learning in 2018 reduced the cost of some non-natural amino acids in the medium-sized production method by less than one third through joint research with Amia. | Facts |
| Manufacturing outsour | In the original medicines of medium-sized antibody modificationsCollaboration with over 10 CDMOs in Japan and overseas(Non-dis)sure) LUNA18 original drug achieves 50kg scale supply jointly with CDMO | Facts |
The investment amount indicated by Chugai as a series of facilities from the drug discovery to production of Chugai、s (including the Yokohama Institute) is LSP 1,288 billion yen, E68 of float 45 billion yen, UKX 800 billion yen (planned), Fujieda FJ 1 70 billion yen, FJ 2 191 billion yen, FJ 3 55 billion yen FactsHome In addition to this, only clinical trial and production facilities and method development functions (FJ1, FJ2, FJ3, E68, UKX)Total: 1,661 billion yenClose The calculation of this paperHome The amount equivalent to 2025’s R&D costs (1,801 billion yen) is the modalities that are not yet elegantHow to make
6. Past Initiatives
| Time | Home | |
|---|---|---|
| December 2001 | Basic Agreement with Shu and Strategic AllianceIn 2002, a comprehensive introduction contract for development and existing products was signed with the merger of Japan Shu | Chugai has a majority stake, and Chugai has kept its shares listed |
| 2003 Year | Fujieda’s original medicine facility FJ (70 billion yen) | Used in the manufacture of clinical trial drugs of medium s |
| 2014 year | Antibody modification technologyDouble-specific antibodies | Our antibody technology itself has become a target for Shu |
| FY2016 | Osaka University IFReC ILes ne izumab (anti-IL-31 receptor A antibody) to galderma | Immunology studies and dermatology |
| Year 2018 | Preferred Networks partnershipNon-peptide-type Oral GLP-1 receptor agonistContact Us | Initiatives for AI drug discovery and guidance in obesity and diabetes |
| 2022 year | Life Science Park Yokohama(1,288 billion yen) and FujiedaFJ2(19 billion yen) | FJ2 receives ISPE’s 2023 Facility of the Year Awards |
| 2023 year | Fuji Field Laboratory and Kamakura Laboratory closed (March). Chugai Venture Fund was established (July) | Osaka Office |
| 2024 views | To FujiedaFJ3(5.5 billion yen) | Equipment for the 3rd phase to initial commercialization of medium-sized products |
| May 2025 | AAV gene therapy "Elevigis" introduced from Shu (Duchenne muscular dystrophy) is a product such as regenerative medicine in JapanTerms and Expiration Approval | Targets are pedestrians between 3 and 8 years old. |
| 2025 years | First mediumDisco development of RAS in LUNA18Home Switch antibody STA551, SOF10, Tricyclic antibody SAIL66, Recycling antibody AMY109 | Management decisions and company descriptions of the status of data and portfolio |
| November 2025 | 3rd phase international joint study of RNAi treatment drug RG6615 (high blood pressure) in Shu and RG6102 (alzheimer's disease) in anti-amyloid β/TfR1 fusion | Antibodies designed to overcome nucleic acid drugs and blood cerebral cor are developed in Japan and later |
| April to May 2026 | Next-generation double-specific antibodyNXT0072 Phase 3 Tests for Hemophilia A | Original antibodies followed by hembrila |
| May 2026 | 3rd mediumAQUA07(ALK-positive lung cancer, arosteric inhibition) acquires the U.S. FDA's Fast Track designation, to Phase 1 | LUNA18 has been disco ed. |
| Second Quarter 2026 | Oral Obesity Drugs of ElililyFOUNDAYO(orforglipron) Royalty Income | Low、s made by Chugai Pharmaceutical Co., Ltd. are profitable as products of other companies. |
Primary clinical trials in progress
| Test (NCT number) | Phase | Comparison contrast | Main evaluation items |
|---|---|---|---|
| ZEBRHA 1（NCT07416526） | Phase 3 Hemophilia A (NXT007) | Periodic rehabilitation therapy with blood coagulation factor VIII | Annual bleeding rate of bleeding (ABR) |
| ZEBRHA 2（NCT07416604） | Phase 3 Hemophilia A (NXT007) | Periodic administration by Emisizumab (Hembola) | Annual bleeding rate of bleeding (ABR) |
All s are and the results are not yet published Undetermined / FutureHome The point of self-developing tests in contrast to our own products is designed and read to switch to next-generation products.
7. Future plans
Global products annuallyCompany Goals
The company indicates three stages: "Development of basic technology" "〜2025" "Development of pharmaceutical platform" "〜2027" Basic production base and pharmaceutical platform construction completed FactsHome In the future, we will aim to reduce production costs and improve development speed in order to increase the .
Both of the following are not listed in the primary material that has been confirmed in this article Undetermined / Future。
R&D expensesModality/Medium/First approval time(LUNA18 was discoed and AQUA07 was phase 1)/ LUNA18to lead/FOUNDAYORoyalty rate and amount/CollaborateCDMOHome We do not use estimates of Chugai’s medium-。 market of ○ billion yen.
8. What is this company aiming for drug discovery and DDS?
This includes parts that the company does not directly state.Calculation in the range that can be read from primary informationand write with the basis.
| Read | Primary Information | |
|---|---|---|
| Medium isPharmaceutical PlatformContact Us | After disco ing the first internal development of the LUNA18 medium , the third medium AQUA07 was clinically entered, and the UKX of 800 billion yen was constructed during emergence. | |
| Medium isMake your own | We switched from solid phase to proprietary liquid phase method, and constructed a high-activity material engineering facility (FJ2) in collaboration with Nippon Volatile and. On the other hand, more than 10 CDMOs collaborate | |
| Other thanGrowing revenue with leads | Lili (oral GLP-1) and Garderma (ne、izumab) have increased sales for the first half of 2026 by export and loyalty | Facts |
| Antibodyyour own products with your next generationReady | NXT007 Test (ZEBRHA 2) | |
| 2025 yearsGreatly organize your early products | LUNA18, STA551, SOF10, SAIL66, AMY109 | Facts |
Chugai’s “Chugai-shaped cyclic peptide” is9-11 residual cyclic peptides that have a high pharmacological activity of about 3 times less than non-natural amino acids and low molecular weights.Design FactsHome The company first is common in peptidesSolid Phase SynI used it, but it is difficult to produce mass production because of the high manufacturing cost. Non-natural amino acids are highly fat-soluble (soluble in organic solvents).Syn of the same liquid phase as a lowWe developed a way to connect fragments in . As a result, we have established a process to obtain LUNA18's original drug at 99.1% purity, and we have explained that the number of manufacturing processes has been reduced by half in the latest engineering. LUNA18 was discoed in 2025.This method and facility can be used as is for the following mediums:HOME This article is not a bet to a single item,"Investment in the Platform of Making"read Undetermined / FutureHome However, there is no product approved by medium。s, and it depends on the future of clinical practice.
9. Collaboration mapping of drug discovery and DDS
10. Technologies, Products and Services
| Technology | Home | Status (indication of securities reports and briefing materials) |
|---|---|---|
| Hem Liver (Emisizumab) | Double-specific antibodies (combined to the X Factor and substitute the function of the VIII Factor) | Approved. Exports reached ¥3,393 billion for 2025. |
| NXT007（zemocimig） | Next-generation double-specific antibody | Developed (3rd phase, 2026) |
| Enspring | pH-dependent modified antibody (anti-IL-6 receptor) | Approved. Our company |
| RAY121／GYM329 | Recycling Antibody (anti-completion C1s)/Sweeping Antibody (anti-potential myostatin) | Developed (1st phase / 2nd phase) |
| AQUA07 | Medium) (cyclic peptide) | AQUA07 LUNA18 was disco ed in 2025. |
| orforglipron（FOUNDAYO） | Non-peptide type oral GLP-1 receptor actuator (low)) | Leading to our own creation and royalty income from Q2 2026 |
| AAV gene therapy (regenerative medicine products) | Introduction from Shu. Terms and Expiration Approval (May 2025) | |
| RG6615／RG6102 | RNAi therapy/anti-amyloid beta/TfR1 fusion protein | Introduction from Shu. Three Phase International Joint Investigation (Started November 2025) |
The original medicine of peptide medicine is fixed one end of the amino acid to the resin and connect one by one.Solid Phase Synis common. Chugai first used this method, according to the company descriptionA large amount of amino acids and reagents are required, and the production cost is high, it is difficult to mass produce, and the liquid phase equipment and know-how that we have for high-activity low solvents is not availableThere was a problem FactsHome Therefore, the company is a medium-to-in cyclic peptideNon-natural amino acids are highly fat-soluble and melt into organic solvents as common low solventsContact Us We developed a method of purification by ringing and crystallization. When purified by crystallization, it is more suitable for mass production when relying on chromatography purification.
Another thing isContact UsBecause the medium has high pharmacological activity, it is necessary to treat large amounts while working.Air concentration: 2μg/m3 or lessIt is assumed that the e tion is achieved FactsHome In the viewpoint of materials and equipment manufacturers,The supply of non-natural amino acids (collaborative research costs less than one-third), liquid-phase condensation and solvents, crystallization conditions, and high-enclosed isolators.However, it is the area that comes into effect by mass production of medium s. Please refer to the technical explanation of this series "Peptide Medicine and GLP-1" and "GMP".
11. Risks that this company has
| Risks | ||
|---|---|---|
| Dependence on the parent company. | The parent company owns 61.12% of the rights and has the first choice for the development and sale of their own products outside Japan. Hem Livera's exports account for a large portion of overseas sales. | Facts |
| Reduction of export unit price | In the financial statement for the first half of 2026, the company is decreasing the export unit price | Facts |
| Revised drug prices and subsequent products in Japan | The company explains that domestic sales are affected by drug price revision and subsequent product penetration | Facts |
| Disco ation of early-stage products | LUNA18, STA551, SOF10, SAIL66, and AMY109 were discovered in 2025. | Facts |
| investment collection | Total of 1,661 billion yen in medium-、 manufacturing and manufacturing facilities, but no approved medium-、 yet. | The calculation of this paper |
| Generation of main products | NXT007 performs a test in contrast to Hem Liver, and if successful, it can compete with your main product |
12. Glossary
- Medium
- Medicine of the middle size of the antibody with low。s (many of the drinker). Chugai is a ring peptide of 9-11 residues.
- Double specific antibodies
- Antibodies that have been modified so that two types of targets can be combined with one antibody. Hem Liver
- Recycling Antibody
- Antibodies that have been altered so that antigens are released in cells and returned to the blood again and can be combined with repeated antigens.
- Swiping Antibody
- Antibodies that have been modified to remove (sweep) the antigen in the blood.
- Solid Phase Syn / Liquid Phase Syn
- A solid phase is a method that connects amino acids on a resin, and the liquid phase reacts in a solution. The latter may be suitable for mass production.
- First choice
- The right to decide whether or not to introduce the candidates from other companies.
- CDMO
- Contract Development A company contracted to develop and manufacture pharmaceutical products.
- Terms and Expiration Approval
- Japan's approval system recognized by conditions and deadlines when the effectiveness of regenerative medicine and other products is and safety has been improved.
Concept diagram of AI generation13. Source
- Pharmaceuticals Securities Report (from January 1 to December 31, 2025 and March 25, 2026). Management indicators, number of employees, company's rights ratio of the parent company, basic contract with the parent company, first choice, technology entry and exit, contract with university and AI company, research and development activities, and disclosed products, capital investment and facility planning, and history. https://www.chugai-pharm.co.jp/cont_file_dl.php?f=FILE_1_76.pdf&src=%5B%250%5D,%5B%251%5D&rep=127,76
- Pharmaceuticals Financial Results for the Fiscal Year Ended December 31, 2025 (January 29, 2026). Export and development progress for Hem Livera of the parent company in 2026. https://www.chugai-pharm.co.jp/cont_file_dl.php?f=FILE_5_74.pdf&src=%5B%250%5D,%5B%251%5D&rep=119,74
- Pharmaceuticals Financial Results for the Second Quarter of the Fiscal Year Ending December 31, 2019 (July 24, 2026). Third phase start of FOUNDAYO, NEMLUVIO, AQUA07, NXT007 https://www.chugai-pharm.co.jp/cont_file_dl.php?f=FILE_5_77.pdf&src=%5B%250%5D,%5B%251%5D&rep=119,77
- Pharmaceuticals Sustainability briefing material "Construction of the pharmaceutical platform for Chubu Pharmaceuticals" (November 27, 2025). Characteristics of medium- and external cyclic peptides, conversion from solid phase。 to liquid phase。, LUNA18 original medicine, collaboration with CDMO, FJ2 e。tion and capital investment https://www.chugai-pharm.co.jp/cont_file_dl.php?f=FILE_1_167.pdf&src=%5B%250%5D,%5B%251%5D&rep=117,167
- ClinicalTrials.gov ZEBRHA 1（NCT07416526）。 https://clinicaltrials.gov/study/NCT07416526
- ClinicalTrials.gov ZEBRHA 2（NCT07416604）。 https://clinicaltrials.gov/study/NCT07416604
- Pharmaceuticals Official website (name and logo) https://www.chugai-pharm.co.jp/
14. Response table of claims and sources
| Content | ||
|---|---|---|
| 900 employees at Chugai Life Science Park Yokohama | Facts | Source 1 https://www.chugai-pharm.co.jp/cont_file_dl.php?f=FILE_1_76.pdf&src=%5B%250%5D,%5B%251%5D&rep=127,76 |
| The parent company owns 61.12% of the rights, basic contract (2001), mutual first choice, and cooperative obligation to maintain listing. | Facts | Source 1 https://www.chugai-pharm.co.jp/cont_file_dl.php?f=FILE_1_76.pdf&src=%5B%250%5D,%5B%251%5D&rep=127,76 |
| UT3, UK3, UKX | Facts | Source 1 https://www.chugai-pharm.co.jp/cont_file_dl.php?f=FILE_1_76.pdf&src=%5B%250%5D,%5B%251%5D&rep=127,76 |
| Earnings forecast for 2026 (Revenue revenue: 13.45 billion yen, Core operating income: 6.37 billion yen), export for Hem Livera: 3,393 billion yen | Facts | Source 2 https://www.chugai-pharm.co.jp/cont_file_dl.php?f=FILE_5_74.pdf&src=%5B%250%5D,%5B%251%5D&rep=119,74 |
| Sales revenue for the first half of 2026: 6,633 billion yen, operating income: 3,291 billion yen, FOUNDAYO’s loyalty record, NEMLUVIO, reduced export unit price | Facts | Source 3 https://www.chugai-pharm.co.jp/cont_file_dl.php?f=FILE_5_77.pdf&src=%5B%250%5D,%5B%251%5D&rep=119,77 |
| AQUA07 Fast Track Designation and Phase 1 Launch of NXT007 Phase 3 | Facts | Source 3 https://www.chugai-pharm.co.jp/cont_file_dl.php?f=FILE_5_77.pdf&src=%5B%250%5D,%5B%251%5D&rep=119,77 |
| The antibody modification technology and the double-specific antibody to the parent company, derived to Galderma (2016) and Erilyli (2018) | Facts | Source 1 https://www.chugai-pharm.co.jp/cont_file_dl.php?f=FILE_1_76.pdf&src=%5B%250%5D,%5B%251%5D&rep=127,76 |
| Agreement with Osaka University IFREC (2016) and Preferred Networks (2018), Acquisition of Chugai Venture Fund and Renaris Pharma | Facts | Source 1 https://www.chugai-pharm.co.jp/cont_file_dl.php?f=FILE_1_76.pdf&src=%5B%250%5D,%5B%251%5D&rep=127,76 |
| LUNA18・STA551・SOF10・SAIL66・AMY109 | Facts | Source 1 https://www.chugai-pharm.co.jp/cont_file_dl.php?f=FILE_1_76.pdf&src=%5B%250%5D,%5B%251%5D&rep=127,76 |
| Low cost of non-natural amino acids, CDMO 10 or more | Facts | Source 4 https://www.chugai-pharm.co.jp/cont_file_dl.php?f=FILE_1_167.pdf&src=%5B%250%5D,%5B%251%5D&rep=117,167 |
| FJ2 edition (0.05μg/m³ or less), collaboration with Nichivola and Shu, ISPE awards, investments per facility, and three stages of pharmaceutical platform | Facts | Source 4 https://www.chugai-pharm.co.jp/cont_file_dl.php?f=FILE_1_167.pdf&src=%5B%250%5D,%5B%251%5D&rep=117,167 |
| Total investment of medium-sized clinical trial and production facilities and method development functions: 166 billion yen | The calculation of this paper | FJ1, FJ2, FJ3, E68, UKX |
| ZEBRHA 1・2 comparison contrast, key evaluation items, sponsor must be Shu | Facts | Source 5・6 https://clinicaltrials.gov/study/NCT07416604 |
| As a result of the ZEBRHA test, the initial approval time of medium s, the royalty rate and amount of FOUNDAYO, the company name of CDMO, and the translation of modalities of R&D expenses | Undetermined / Future | Not specified in the source 1-6. This article does not estimate https://clinicaltrials.gov/study/NCT07416526 |
| Drug discovery and DDS classification (pharmaceu company / drug discovery biotech / contract development manufacturing and research) | The calculation of this paper | This article. Company name is an example of a company handled by this series. |
| Read about how to continue to be a pharmaceutical platform from the success of one item, and how to make it. | LUNA18Consideration of this article from the clinical enrollment of AQUA07 after discovery, UKX's invention, method and equipment | |
| The risk of generational exchanges is read that we are preparing to replace our products with our next generation products. | Interpre of this article from comparison contrast of ZEBRHA 2 |
Last Updated:September 26, 2026/Troy Technical
All the figures in this article are based on the financial statements, financial briefing materials, briefing materials published by Chugai Pharmaceutical and the information provided by ClinicalTrials.gov. We do not use estimates and media-based numbers of survey companies. The "、ulation" section is an interpretation that the article reads from the primary information and is not an announcement of the company. This article is not medical advice.